Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Growth Hormone Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy PSM027

    Growth Disorders Growth Hormone Short-Acting Products Preferred Specialty Management Policy

    Customize your policy alerts

    Sign up for Cigna Policy PSM027 alerts

    Get alerted when Policy PSM027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred-product selection and exception review for short-acting somatropin products under Cigna-administered health benefit plans. Patients must meet the applicable standard prior authorization criteria, and non-preferred products generally require prior trial and intolerance of preferred products.

    Policy Summary
    PayerCigna
    PolicyGrowth Disorders Growth Hormone Short-Acting Products Preferred Specialty Management Policy
    Policy CodePolicy PSM027
    Change TypeMaterial coverage update
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionTry both preferred products, Genotropin and Omnitrope, before requesting a non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    A preferred specialty management program was established for short-acting growth hormone products.

    Saizen was removed from the policy as obsolete.

    2Preferred products
    4Non-preferred products
    6Short-acting somatropin products listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1
    Listed product discontinued

    Coverage Criteria

    Preferred Product Coverage

    Covered when the patient meets the applicable standard prior authorization criteria.

    Preferred-product authorization

    • Patient meets the standard Growth Disorders - Growth Hormone Prior Authorization Policy criteria.
    • Preferred-product sequencing

      • The requested product is Genotropin or Omnitrope.
      • The patient has not tried a preferred product; authorization may be issued for Genotropin or Omnitrope.

    Non-Preferred Product Exception

    A non-preferred product is medically necessary only when all applicable exception requirements are met.

    Non-preferred product exception

    • Patient meets the standard Growth Disorders - Growth Hormone Prior Authorization Policy criteria.
    • Preferred-product trials and intolerance

      • Patient has tried both Genotropin and Omnitrope.

        Documentation required.

      • Patient cannot continue to use both Genotropin and Omnitrope because of a formulation difference in inactive ingredient(s), such as differences in a stabilizing agent, buffering agent, and/or surfactant, that the prescriber believes would result in a significant allergy or serious adverse reaction.

        Documentation required.

    A non-preferred product exception that does not meet all stated exception criteria is not medically necessary.

    Services submitted without applicable covered diagnosis or procedure codes may be denied as not covered.

    Non-preferred short-acting growth hormone products are considered not medically necessary when the applicable non-preferred product exception criteria are not met.

    Provider Actions

    Prior Authorization

    Standard Prior Authorization Required

    Standard prior authorization is required for all Growth Hormone Short-Acting Products, including both Preferred and Non-Preferred Products. The patient must meet the applicable standard Growth Disorders Growth Hormone Prior Authorization Policy criteria.

    • Preferred Products: Genotropin and Omnitrope
    • Non-Preferred Products: Humatrope, Norditropin, Nutropin AQ, and Zomacton
    Step Therapy

    Preferred Products First

    When the patient meets the standard prior authorization criteria but has not tried the Preferred Products, request approval for a Preferred Product rather than a Non-Preferred Product.

    • Require trial of both Genotropin and Omnitrope before approval of a Non-Preferred Product.

    Background

    Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, and Zomacton are somatropin products that are exact reproductions of endogenous human growth hormone. They are considered clinically equivalent, with differences primarily involving delivery devices, dose increments, and storage requirements.

    Definitions

    Preferred Product
    DefinitionA product designated for use before a non-preferred product under the specialty management program.
    Program rolePatients are directed to try the preferred product before approval of a non-preferred product.
    Preferred productsGenotropin and Omnitrope.
    Non-Preferred Product
    DefinitionA product that requires the standard prior authorization criteria plus an approved exception when the patient has not successfully used the preferred products.
    Standard requirementThe patient must meet the applicable standard Growth Disorders Growth Hormone Prior Authorization Policy criteria.

    Initial Authorization

    Initial Authorization

    Initial authorization requires standard prior authorization review and preferred-product sequencing.

    Initial therapy

    • Patient meets the applicable standard Growth Disorders - Growth Hormone Prior Authorization Policy criteria.
    • Product pathway

      • For a preferred product, Genotropin or Omnitrope, authorization may be issued when the patient has not tried a preferred product.
      • Non-preferred product pathway

        • Patient has tried both Genotropin and Omnitrope.

          Documentation required.

    Preferred-Product Sequencing

    StepPreferred products to tryRequirement before requesting a non-preferred product
    1Genotropin and OmnitropeTry both preferred products before approval of a non-preferred product.
    Policy Summary
    PayerCigna
    PolicyGrowth Disorders Growth Hormone Short-Acting Products Preferred Specialty Management Policy
    Policy CodePolicy PSM027
    Change TypeMaterial coverage update
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionTry both preferred products, Genotropin and Omnitrope, before requesting a non-preferred product.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial AuthorizationPreferred-Product Sequencing
    Documentation Required

    Supporting Documentation

    Submit patient-specific supporting documentation when required by the criteria. Previously submitted documentation may satisfy the requirement if it was received during a prior coverage review.

    • Chart notes
    • Prescription claims records and/or prescription receipts
    • Other relevant patient-specific information
    • All documentation must include patient-specific identifying information
    Documentation Required

    Document Preferred-Product Trials and Intolerance

    For a Non-Preferred Product exception, document that the patient tried both Genotropin and Omnitrope and that the prescriber determined the patient cannot continue both Preferred Products because of intolerance or treatment failure. When the issue is formulation-related, document the inactive-ingredient difference and the resulting significant allergy or serious adverse reaction.

    • Document trials of Genotropin and Omnitrope.
    • Document prescriber determination of intolerance, treatment failure, or inability to continue treatment, as applicable.
    • For formulation-related intolerance, identify differences in inactive ingredients such as stabilizing agents, buffering agents, or surfactants.
    • Documentation is required for the product trials and the prescriber-determined significant allergy or serious adverse reaction.
    Denial Risk

    Failure to Meet Coverage or Exception Criteria

    Requests may be denied when the patient does not meet the applicable standard Growth Disorders Growth Hormone Prior Authorization Policy criteria or when required Preferred-Product trial, documentation, or exception requirements are not satisfied.

    • All approvals are limited to the duration authorized under the applicable standard prior authorization criteria.
    • If standard criteria are met but Preferred-Product trials have not occurred, authorize review of Genotropin or Omnitrope under the applicable standard criteria instead of approving a Non-Preferred Product.
    Denial Risk

    Unmet Non-Preferred Exception

    A Non-Preferred Product exception request that does not meet the stated exception criteria is considered not medically necessary. The exception requires standard prior authorization eligibility plus trials of both Genotropin and Omnitrope and documented inability to continue both Products due to the qualifying formulation-related intolerance or serious adverse reaction.

    • Any other Non-Preferred Product exception is considered not medically necessary.
    Exception requirement
    The patient must meet the applicable non-preferred product exception criteria for coverage.
    Patient cannot continue to use both Genotropin and Omnitrope because of a formulation difference in inactive ingredient(s), such as differences in a stabilizing agent, buffering agent, and/or surfactant, that the prescriber believes would result in a significant allergy or serious adverse reaction.

    Documentation required.